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ABSTRACT
Aims and background.The social cost of management of patients suffering from col-
orectal cancer has been growing dramatically in the last decade due to the high num-
ber of active antitumor agents and to the increased incidence of the tumor in western
countries. The aim of the study was to explore from a pharmacoeconomic point of
view a different way to administer the two most common regimens in this patient set-
ting.
Study design. This was a cost-minimization study. Data were extracted from hospital
registries and dedicated offices. The traditional setting (day hospital inpatient setting)
and a fully ambulatory setting (CIP™ pump) were considered and compared.
Results.The CIP™ system resulted in higher direct costs than the day hospital setting
(444.70 vs 159.00 euro/cycle). However, traditional infusion resulted in longer nursing
care, with an increase in nursing costs of more than 100.00 euro/cycle. Moreover, the
inpatient setting obliged patients to stay in the hospital as much as ten times longer
than with the CIP™ system. This meant that with the same time span and the same
resources, the CIP™ pump permitted treatment of at least five times more patients
than the traditional setting. Thus, a threshold of 52.00 euro per patient for general
hospital costs (ordinary and extraordinary maintenance of buildings, power supply,
and housekeeping) was identified to discriminate whether the CIP™ pump is cost-
saving or not.
Conclusions. Administration of the FOLFIRI or FOLFOX regimen in a traditional
day hospital setting was less costly when considering the direct costs. However, a
fully ambulatory pump permitted to better employ hospital resources and could
permit cost-saving in those units in which more than five patients per day are treat-
ed and global costs are higher than 52.00 euro per patient. Free full text available at
www.tumorionline.it
Introduction
The management of patients suffering from colorectal cancer has considerably
changed in the last decade. The introduction of irinotecan and oxaliplatin, and more
recently of the new biological agents cetuximab and bevacizumab has improved pa-
tient outcome in the adjuvant and in the metastatic setting1. This increase in treat-
ment efficacy could be the principal mechanism underlying the described decrease
in cancer mortality despite the rise in the number of new cases per year2,3.
Since the late ‘60s, the backbone of all chemotherapeutic regimens has been 5-fluo-
rouracil (5-FU)4. The pharmacokinetics of 5-FU is well known. Toxicity and efficacy
profiles of the compound differ according to whether it is administered with a bolus or
an infusional scheme. In particular, infusional administration has been demonstrated
to be more active with fewer side effects5,6. Today the FOLFOX and FOLFIRI regimens
combined or not with biologic agents are the gold standard4. These regimens consist
Tumori, 96: 438-442, 2010
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in the combination of oxaliplatin (FOLFOX) or irinote-
can (FOLFIRI) with bolus and infusional 5-FU modulat-
ed by folinic acid (Figure 1). They could be administered
in a fully inpatient setting or on a day hospital basis with
ambulatory pumps. The former solution is being aban-
doned due to high social and psychological costs, and
most patients are treated on a day hospital basis. In this
case, oxaliplatin or irinotecan, folinic acid and 5-FU bo-
lus are administered in hospitals in a traditional way
with solutions, whereas 5-FU infusion is made possible
through ambulatory pumps. Several devices have been
proposed to permit 5-FU infusion at home: electronic
pumps, more costly and more precise, and elastomeric
pumps, less costly but less precise. Factories have now
abandoned the development of electronic pumps, fo-
cusing their attention on new elastomeric devices that
could represent a good compromise between infusion
precision and cost savings.
However, it should be noted that the incidence of col-
orectal tumors is growing with public health costs,
which are dramatically increasing. Thus, every new way
to administer FOLFOX or FOLFIRI regimens should be
carefully considered from a pharmacoeconomic point
of view7. For an Oncologic Unit which administers more
than 1000 FOLFOX or FOLFIRI regimens per year, the
choice of a less expensive pump could represent a con-
siderable cost savings. However, a real public health
cost savings is represented by a radical change in the
management of these patients by reducing their time in
the hospital. This might be possible using disposable
devices that manage folinic acid and bolus 5-FU and in-
fusional 5-FU administration, and, even better, dispos-
able devices that can administer the complete scheme
(oxaliplatin or irinotecan, bolus and infusional 5-FU
and folinic acid) in a fully ambulatory setting. In this
way, hospital resources would be better employed with
a more rational distribution of work, making it possible
to satisfy more patients than would be followed in the
same time span.
In this cost minimization study, we considered the
pharmacoeconomic aspects of a new device (CIP™
pump, H.S. Hospital Service S.p.A., Rome, Italy) that al-
lows administration of FOLFOX and FOLFIRI regimens
in a fully ambulatory setting.
Materials and methods
We took into consideration two different ways of ad-
ministering the FOLFOX or FOLFIRI regimen: the tradi-
tional setting and the fully ambulatory CIP™ pump.
These regimens consist of a 1 h 30 min infusion of oxali-
platin or irinotecan on day 1, of a 2-h infusion of folinic
acid on days 1 and 2, of a 15 min bolus infusion of 5-FU
on days 1 and 2, and of 44 hr continuous 5-FU infusion
(Figure 1)8. Usually, supportive care such as antiemetics
are administered as an infusion in the traditional setting
with additional 30-40 min of patient care time, whereas
they are administered per os in the CIP setting.
In the traditional setting, drugs are infused in differ-
ent solutions: 500 cc of 5% glucose for oxaliplatin (or
500 cc of NaCl isotonic solution for irinotecan), 250 cc of
5% glucose for 5-FU bolus, 500 cc of NaCl solution for
folinic acid, and an elastomeric pump with no more
than 84 cc of 5% glucose solution for 5-FU continuous
infusion. CIP pumps consist of 4 elastomeric 160 cc
pumps filled with drugs (oxaliplatin or irinotecan, folin-
ic acid and 5-FU) diluted in 5% glucose or NaCl solution
as appropriate.
In this cost minimization study aimed to verify which
form of administration of the same regimen permits
higher cost savings, we did not consider drug, central
venous catheter or needles and disinfectant costs in the
final computation as they do not differ in the two treat-
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Figure 1 - Infusional scheme of the FOLFOX or FOLFIRI regimens.
- Copyright - Il Pensiero Scientifico Editore downloaded by  UniTO IP 130.192.124.93 Mon, 06 May 2013, 10:44:27
ments considered. All costs are expressed in 2008 Euro
and VAT is included.
Hospital costs
Costs of solutions, syringes and infusional pumps
were obtained from the Pharmacy registries. Nurse and
doctor staff costs as well as meal and inpatient electron-
ic pump costs were provided by the Hospital manage-
ment control office, particularly dedicated to control
money fluxes. Drug, solution, and pump preparation
protocols were defined according to the Oncologic Unit
of AOU San Luigi Gonzaga, Orbassano, Torino, Italy and
compared to major Hospitals in the Piedmont region.
Infusional times are those indicated in the literature,
whereas nursing times were measured as follows: for
each preparation protocol (drug dilution, solution and
infusional set preparation, filling of the pumps), the
time employed by four different nurses for at least twice
a day for three days was recorded on a file. The average
time was considered in the study.
CIP™ pump
The device consists of two to four elastomeric pumps
connected to a four-way disposable electronic control
unit which independently manages drug flow according
to a factory presetting scheme. The unit is powered by
two alkaline AAA batteries that are included in the kit
together with a specially designed bag. All the material
is disposable. The cost of the kit was provided by H.S.
Hospital Service S.p.A., Rome, Italy, which produces and
merchandises the pump in the Italian market.
Pump preparation consisted of filling up four elas-
tomeric pumps, one with oxaliplatin diluted with 5%
glucose, one with folinic acid diluted with saline, one
with 5-FU diluted with 5% glucose, and finally one with
5% glucose. Each pump contains 160 ml of solution. At
the time of the study, pharmaceutical presentation of
oxaliplatin and 5-FU was a liquid ready to be diluted,
whereas folinic acid was in a powder form. Elastomeric
pumps had to be connected to the CIP™ device from
which depart four patient lines. Purging is controlled by
the device as the first part of the infusional program.
Purging lasted not more than one minute.
Pump preparation time was determined as stated
above: the average time was considered in the study.
Results
Costs for disposable materials, drug preparation, and
patient care are summarized in Table 1.
Traditional setting
Disposable material costs. Disposable materials con-
sisted of one 500 cc bottle of 5% glucose solution, two
250 cc bottles of 5% glucose solution, two 500 cc bottles
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of NaCl solutions, three 250 cc bottles of NaCl solutions,
three 10 cc syringes, two infusional sets, and one elas-
tomeric pump.
Drug preparation. Oxaliplatin, irinotecan and 5-FU
dilution took not more than 2 min/pharmacist (42.00
euro/hour = 3.50 euro) and 4 min/nurse. Folinic acid di-
lution was more time consuming, accounting for about
6 min/nurse per day (for two days). Infusional set
preparation took 2 min/nurse per day (for two days).
Thus, nurse time for drug preparation was 20 min, for a
final cost of 19.00 euro/hour = 6.33 euro.
Patient care. Medical examination for Day Hospital
admission took 15 min, with an additional 5 min for day
2 check, for a total cost of 47.00 euro/hour = 15.67 euro.
Infusion of iv antiemetics, corticosteroids and gastric
protector accounted for 30 min. Oxaliplatin or irinote-
can are infused in 90 min, 5-FU bolus in 15 min per day
(days 1 and 2), folinic acid in an additional 120 min per
day (days 2 and 2), for a total patient care time of 390 min
per cycle. As oxaliplatin and irinotecan might be infused
with folinic acid contemporarily, we might reduce this
time to 300 min per cycle. Thus, final computed cost was
19.00 euro/hr (nursing care) for 300 min = 95.00 euro.
Table 1 - Direct costs for the administration of FOLFIRI or FOL-
FOX regimen according to a traditional setting or the CIP™
Pump
Disposable material Quantity Cost Total cost
per unit
Traditional
5%glucose 500 cc 1 0.46 € 0.46
5% glucose 250 cc 2 0.40 € 0.80
NaCl 500 cc 2 0.45 € 0.90
NaCl 100 cc 3 0.35 € 1.05
Elastomeric pump 1 26.22 € 26.22
10 cc syringe 3 0.07 € 0.21
Infusional set 2 1.98 € 3.96
Drug preparation Minutes Cost/hr
Pharmacist 2 42.00 € 1.40
Nurse 20 19.00 € 6.33
Patient care
Medical examination day 1 15 47.00 € 11.75
Medical examination day 2 5 47.00 € 3.92
Nurse 300 19.00 € 95.00
Inpatient pump 300 0.20 € 1.00
Meal 1 6.00 € 6.00
Total € 159.00
CIP™ PUMP
NaCl 500 cc 1 0.45 € 0.45
5% glucose 500 cc 1 0.46 € 0.46
10 cc syringe 2 0.07 € 0.14
50 cc syringe 4 0.25 € 1.00
CIP™ pump 1 420.00 € 420.00
Drug preparation
Pharmacist 2 42.00 € 1.40
Nurse 25 19.00 € 7.92
Patient care
Medical examination day 1 15 47.00 € 11.75
Pump positioning 5 19.00 € 1.58
Total € 444.70
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Electronic inpatient pumps for the administration of
iv drugs are frequently employed in Italian hospitals.
The average cost of these pumps is 1,500.00 euro. Con-
sidering a utilization of 6 hr per day, 5 days a week, 50
weeks per year for a maximum of 5 years, pump cost is
0.20 euro per hour. Thus, electronic inpatient pump uti-
lization was 1 euro (0.20 euro/hr for 5 hr).
Finally, patients submitted to chemotherapy in the
traditional setting ate at our Day Hospital, with an addi-
tional cost of 6.00 euro.
On the whole, costs for a FOLFOX or a FOLFIRI regi-
men in a fully Day Hospital setting was 159.00 euro
(Table 1).
CIP™ costs
Disposable material cost. Disposable materials con-
sisted of one 500 cc bottle of 5% glucose solution, one
500 cc bottle of NaCl solution, four 50 cc syringes, two
10 cc syringes, and one CIP™ pump. The pump costs
420.00 euro (350.00 + 20% VAT).
Drug preparation. Oxaliplatin, irinotecan and 5-FU
dilution took not more than 2 min/pharmacist (42.00
euro/hour = 3.50 euro) and 4 min/nurse. An additional
4 min were needed to fill the pump. Folinic acid dilution
accounted for about 10 min and pump filling, 3 min.
Pump setup accounted for 4 min. Thus, nurse occupa-
tion time for drug preparation was 25 min, for a final
cost of 19.00 euro/hour = 7.92 euro.
Patient care. Medical examination for Day Hospital
admission took 15 min, for a total cost of 47.00
euro/hour = 11.75 euro.
Pump positioning accounted for not more than 5
min/nurse for a cost of 1.58 euro.
Final cost for the CIP setting was 444.70 euro (Table 1).
Discussion
The number of patients who need to be treated with a
FOLFOX or a FOLFIRI regimen is growing. Data from
the Tumor Registry of Torino confirm that colorectal
cancer incidence in the town of Torino has increased
from an adjusted rate of 45/year in 1985 to 57.5/year in
2005, with a 28% increase9. The trend has been constant
since the late ‘70s, and it is reasonable to think that it
will continue to increase in the near future. Thus, in
2008 we might expect more than 38,000 new cases in
Italy, 19,000 of them with an indication to either FOL-
FOX or FOLFIRI chemotherapy10. Thus, colorectal can-
cer is becoming a social problem for its psychological,
family, and working implications, but also for the public
health costs. In the era of continuing cost savings, every
aspect of these treatments should be carefully consid-
ered in order to minimize treatment costs9,11-17. Reduc-
tion of the time spent by patients in hospital represents
a valid way to minimize costs, permitting a large num-
ber of patients who need more complicated treatment
to find room in our busy oncologic units and thus in-
crease the quality and quantity of care with comparable
resources.
In our study, the CIP™ pump apparently had a higher
cost. This is obviously true if we consider only the mate-
rial needed to administer chemotherapy and the staff
costs. However, it permitted a significant reduction of
seat or bed occupation with a lower nursing and med-
ical care time that can be estimated in a savings of about
100.00 euro. Thus, as regards materials and direct pa-
tient care, there was a balance of 258.70 euro in favor of
the traditional administration. It should be noted that
the traditional setting accounted for a seat occupation
of at least 300 min with an additional 20 min for drug
preparation, which was 10 times longer than the 30 min
required by nurse for the CIP™ pump. This means that
with the same resources we might treat 10 times as
many patients with the CIP™ pump than with tradi-
tional infusion. Implications in work organization are
easy to understand but they are not the focus of this pa-
per. What is clearly evident is that general costs such as
heating and climatization of hospital buildings, clean-
ing of the oncologic unit and of the common area of the
hospital, garbage management, power supply and wa-
ter costs, ordinary and extraordinary maintenance of
the buildings, administrative and superstructure costs
(such as the medical team ready to take immediate ac-
tion in case of any emergency, the computer network
system, etc.) would be split on a major number of pa-
tients. These general costs are fixed depending on the
total room volume of the entire hospital, the number of
buildings and how they are connected, the number of
patients that can be hospitalized, and on several other
variables.
These costs are the basis of the so-called “basic costs
analyses”, which is extremely complicated and not yet
standardized18. In fact, these analyses have never been
made in our structure, and it is evident that such costs
differ according to the hospital (buildings in southern
Italy have less heating costs than those in the northern
part of the country, for example). In our study, hypothe-
sizing that we might treat 5 patients with the CIP™
pump instead of 1 patient in the traditional setting, it is
sufficient that the general costs for a single day hospital
seat is more than 52.00 euro per cycle – which is easily
the case in our Italian hospitals - to indicate the CIP™
pump as the more cost-saving methodology. Moreover,
we should consider the growing number of patients
who will benefit from these chemotherapy regimens,
which will further lower this threshold as we might ac-
cept 5 more patients with the same nurse, medical and
structural resources.
Acute oxaliplatin and irinotecan toxicity might repre-
sent a major problem for the administration of these
drugs on an outpatient basis. Acute laryngeal spasm,
immunomediated reactions, or acute cholinergic syn-
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drome, although rare, are events that might occur19,20. It
is up to the physician together with the patients to de-
cide whether it is safe or not to deliver oxaliplatin or
irinitecan in a fully ambulatory setting. It should be not-
ed that these acute events are typical in the same pa-
tient and are recorded immediately. Thus, it could be a
good compromise to administer the first two cycles in a
more traditional way and, just in case no acute event is
recorded, to continue on a fully outpatient basis.
The administration of oxaliplatin or irinotecan on an
inpatient basis and folinic acid and 5-FU on an outpa-
tient basis increased the total cost of the CIP™ pump by
28.50 euro (90 min of nurse/care at a cost of 19.00 eu-
ro/hour). Even though this is not the best solution for
minimizing costs, it might be a better way, even from a
pharmocoeconomic point of view, to administer FOL-
FOX or FOLFIRI instead of the traditional way, increas-
ing the general cost threshold by no more than 6.00 eu-
ro. This should be preferred by oncologists who are not
confident with the administration of oxaliplatin and
irinotecan on an outpatient basis, as it reduces social
costs.
Last but not least, it is noteworthy that fully ambulato-
ry pumps can reduce indirect costs such as work capac-
ity reduction, and intangible costs such as a lower im-
pact on the global patient quality of life. In fact, several
patients are active in their social life and many of them
continued to work during therapy administration7.
In conclusion, material and staff costs for the CIP™
pump are higher than for traditional chemotherapy ad-
ministration. However, even not considering indirect
and intangible costs, CIP cost-saving surpassed tradi-
tional infusion when considering general costs and will
be more and more indicated in the future as patients
who will benefit from a FOLFOX or FOLFIRI regimen
will grow in number and there are no more resources to
widen the Public Health offer.
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